Cargando…

Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses

BACKGROUND: SARS-CoV-2 vaccination has proven the most effective measure to control the COVID-19 pandemic. Booster doses are being administered with limited knowledge on their need and effect on immunity. OBJECTIVE: To determine the duration of specific T cells, antibodies and neutralization after 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Almendro-Vázquez, Patricia, Chivite-Lacaba, Marta, Utrero-Rico, Alberto, González-Cuadrado, Cecilia, Laguna-Goya, Rocio, Moreno-Batanero, Miguel, Sánchez-Paz, Laura, Luczkowiak, Joanna, Labiod, Nuria, Folgueira, María Dolores, Delgado, Rafael, Paz-Artal, Estela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428395/ https://www.ncbi.nlm.nih.gov/pubmed/36059485 http://dx.doi.org/10.3389/fimmu.2022.981350

Ejemplares similares

A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID
por: Utrero-Rico, Alberto, et al.
Publicado: (2021)

Alterations in Circulating Monocytes Predict COVID-19 Severity and Include Chromatin Modifications Still Detectable Six Months after Recovery
por: Utrero-Rico, Alberto, et al.
Publicado: (2021)

Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination
por: Almendro-Vázquez, Patricia, et al.
Publicado: (2021)

Defending against SARS-CoV-2: The T cell perspective
por: Almendro-Vázquez, Patricia, et al.
Publicado: (2023)

Hemodialysis-Associated Immune Dysregulation in SARS-CoV-2-Infected End-Stage Renal Disease Patients
por: González-Cuadrado, Cecilia, et al.
Publicado: (2023)

Tolerogenic Role of Myeloid Suppressor Cells in Organ Transplantation
por: Ochando, Jordi, et al.
Publicado: (2019)

Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
por: Luczkowiak, Joanna, et al.
Publicado: (2022)

Immune Response Against SARS-CoV-2 Infection and Vaccination in a CD8α-Deficient Patient
por: Arroyo-Sánchez, Daniel, et al.
Publicado: (2023)

SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy
por: Lledó, Ana, et al.
Publicado: (2021)

Discordance Between SARS-CoV-2–specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients
por: Fernández-Ruiz, Mario, et al.
Publicado: (2021)

The role of DC-SIGN as a trans-receptor in infection by MERS-CoV
por: Labiod, Nuria, et al.
Publicado: (2023)

Decreased breadth of the antibody response to the spike protein of SARS-CoV-2 after repeated vaccination
por: Horndler, Lydia, et al.
Publicado: (2023)

IL-6–based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts
por: Utrero-Rico, Alberto, et al.
Publicado: (2021)

Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19–Convalescent Individuals
por: Luczkowiak, Joanna, et al.
Publicado: (2021)

IL-6–based mortality risk model for hospitalized patients with COVID-19
por: Laguna-Goya, Rocio, et al.
Publicado: (2020)

Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals
por: Luczkowiak, Joanna, et al.
Publicado: (2021)

Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency
por: Arroyo-Sánchez, Daniel, et al.
Publicado: (2021)

Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19
por: Folgueira, Maria Dolores, et al.
Publicado: (2021)

Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern
por: Luczkowiak, Joanna, et al.
Publicado: (2022)

Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome
por: Pleguezuelo, Daniel E., et al.
Publicado: (2021)

Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients
por: Chumsri, Saranya, et al.
Publicado: (2021)

Perforin gene variant A91V in young patients with severe COVID-19
por: Cabrera-Marante, Oscar, et al.
Publicado: (2020)

Inborn Error of STAT2-Dependent IFN-I Immunity in a Patient Presented with Hemophagocytic Lymphohistiocytosis and Multisystem Inflammatory Syndrome in Children
por: López-Nevado, Marta, et al.
Publicado: (2023)

Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination
por: Tauzin, Alexandra, et al.
Publicado: (2023)

An Early Th1 Response Is a Key Factor for a Favorable COVID-19 Evolution
por: Gil-Etayo, Francisco Javier, et al.
Publicado: (2022)

DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist
por: Thépaut, Michel, et al.
Publicado: (2021)

TLR7 Activation in M-CSF-Dependent Monocyte-Derived Human Macrophages Potentiates Inflammatory Responses and Prompts Neutrophil Recruitment
por: Simón-Fuentes, Miriam, et al.
Publicado: (2023)

Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome
por: Villalaín, Cecilia, et al.
Publicado: (2020)

Cellular and Humoral Immune Responses after Breakthrough Infection in Patients Undergoing Hemodialysis
por: Toda, Masataro, et al.
Publicado: (2023)

Cell-mediated and Neutralizing Antibody Responses to the SARS-CoV-2 Omicron BA.4/BA.5–adapted Bivalent Vaccine Booster in Kidney and Liver Transplant Recipients
por: Fernández-Ruiz, Mario, et al.
Publicado: (2023)

Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses
por: Lasala, Fátima, et al.
Publicado: (2021)

Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
por: Gonzalez-Perez, Maria, et al.
Publicado: (2022)

The patent dispute over the breakthrough mRNA technology
por: Aquino-Jarquin, Guillermo
Publicado: (2022)

Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells
por: Kwan, Wing-hong, et al.
Publicado: (2013)

Breakthrough infection shapes humoral immunity against SARS-CoV-2 Omicron Variant
por: Zhang, Yuwei, et al.
Publicado: (2023)

mRNA-1273/ravulizumab: Breakthrough haemolysis: case report
Publicado: (2021)

The Leishmania infantum PUF proteins are targets of the humoral response during visceral leishmaniasis
por: Folgueira, Cristina, et al.
Publicado: (2010)

SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection
por: Pušnik, Jernej, et al.
Publicado: (2023)

Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine
por: Mwimanzi, Francis, et al.
Publicado: (2023)

Renal Transplantation Dramatically Reduces IgA Anti-beta-2-glycoprotein I Antibodies in Patients with Endstage Renal Disease
por: Serrano, Manuel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o6o3is20ehthm5enfl80vasllc